Skip to main content

Peer Review reports

From: Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol

Original Submission
3 Feb 2022 Submitted Original manuscript
4 Apr 2022 Author responded Author comments - Emilie THIVAT
Resubmission - Version 2
4 Apr 2022 Submitted Manuscript version 2
Publishing
6 Apr 2022 Editorially accepted
15 Apr 2022 Article published 10.1186/s12885-022-09495-3

You can find further information about peer review here.

Back to article page